Skip to main content

Table 3 First-Line and Second-Line Treatment Regimens

From: Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom

Regimen Patients, n (%)
1 L therapy
(n = 1003)
2 L therapy
(n = 287)
Chemotherapy
 Carboplatin-based doublet or triplet therapya 499 (49.8) 57 (19.9)
 Carboplatin 3 (0.3) 0
 Cisplatin-based doublet or triplet therapya 172 (17.1) 7 (2.4)
 Docetaxel 5 (0.5) 17 (5.9)
 Docetaxel + nintedanib 4 (0.4) 16 (5.6)
 Gemcitabine 3 (0.3) 1 (0.3)
 Nintedanib 0 1 (0.3)
 Paclitaxel 0 4 (1.4)
 Pemetrexed 9 (0.9) 0
 Vinorelbine 3 (0.3) 1 (0.3)
Immuno-oncology therapy
 Atezolizumab 0 32 (11.1)
 Nivolumab 5 (0.5) 20 (7.0)
 Pembrolizumab 174 (17.3) 96 (33.4)
Targeted therapyb
 Afatinib 67 (6.7) 5 (1.7)
 Alectinib 2 (0.2) 2 (0.7)
 Ceritinib 6 (0.6) 3 (1.0)
 Crizotinib 11 (1.1) 4 (1.4)
 Erlotinib 12 (1.2) 5 (1.7)
 Gefitinib 24 (2.4) 3 (1.0)
 Osimertinib 4 (0.4) 13 (4.5)
  1. 1 L first line; 2 L second line; ALK anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; IV intravenous, ROS ROS proto-oncogene 1
  2. a Triplet therapy indicates carboplatin (IV) + vinorelbine (IV) + vinorelbine (oral), cisplatin (IV) + vinorelbine (IV) + vinorelbine (oral), or cisplatin (IV) + etoposide (IV) + etoposide (oral)
  3. b EGFR, ALK, or ROS inhibitor